Broadcom named strategic vendor for Walmart virtualization solutions
Bruno Julianne, the Chief Operating Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), a biotechnology company currently valued at $3.7 billion, recently executed a series of stock transactions involving the company’s common shares. According to InvestingPro data, the stock has shown significant volatility, trading between $36.52 and $76.86 over the past 52 weeks. According to a recent SEC filing, Julianne sold a total of 1,388 shares, generating proceeds of $59,049. The sales occurred on March 11 and March 12, with the shares sold at prices ranging from $42.42 to $43.32 per share, close to the current trading price of $43.49.
In addition to the sales, Julianne also acquired shares through the exercise of restricted stock units. On March 10 and March 11, Julianne acquired a total of 2,834 shares. These transactions were part of a pre-determined schedule, as indicated by the filing. Following these transactions, Julianne holds a direct ownership of 8,508 shares in the company. For deeper insights into insider trading patterns and comprehensive analysis, including 8 additional ProTips about CRISPR Therapeutics, check out the detailed research available on InvestingPro.
In other recent news, CRISPR Therapeutics has been the focus of several analyst updates and strategic evaluations. Evercore ISI upgraded CRISPR Therapeutics from an In Line to an Outperform rating, raising the price target to $99, driven by optimism about upcoming catalysts in the company’s pipeline. This includes the potential of in vivo programs CTX320 and CTX310, with probabilities of success assigned at 10% and 5%, respectively. Similarly, Citi maintained a Buy rating but adjusted the price target to $82, noting the expansion of Casgevy treatment centers globally and the anticipated catalysts in 2025.
Conversely, Stifel reduced their price target to $49, maintaining a Hold rating due to cautious expectations regarding Casgevy’s market uptake. They highlighted the importance of safety in in vivo gene editing treatments and the potential positive developments in the pipeline. Meanwhile, TD Cowen upgraded CRISPR Therapeutics from Sell to Hold, with a steady price target of $35, citing reduced downside risk and emphasizing the need for management to demonstrate the value of their pipeline.
These developments underscore the mixed sentiment among analysts regarding CRISPR Therapeutics’ future prospects, with varying expectations for its gene-editing therapies and pipeline advancements. Investors are closely monitoring the company’s progress, especially concerning Casgevy’s launch and the potential impact of in vivo program data expected in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.